Purpose: The objective of this systematic review was to verify whether the local or systemic administration of antisclerostin improves the osseointegration of dental or orthopedics implants and stimulates bone remodeling. Materials and Methods: An extensive electronic search was conducted through MEDLINE (PubMed®), PubMed Central® and Web of Science® databases, and specific Journals peer-reviewed to identify case report, case series, randomized controlled trial, clinical trial, and animal studies comparing either the systemic or local administration of antisclerostin with no use, in control group to determine the effect in osseointegration and bone remodeling. Articles in English and with no restriction of period were included. The focused question was determined according to PICO strategy. Results: Twenty articles were included for full review. One out of the twenty was excluded and 19 articles were included in the study, of which 16 were animal studies and 3 were randomized control trials (RCTs). Three of the 16 animal studies reported two different studies, remaining with 19 animal studies and 3 RCTs to analysis. Those studies were divided into two groups, one to evaluate the osseointegration proprieties and the other to verify the bone remodeling potential. Conclusion: The antisclerostin appears to be a promising treatment option to accelerate the osseointegration of dental implants and/or improve the bone neoformation when are present pathologies that could lead to loss of bone structure.
|Date of Award||15 Dec 2021|
- Universidade Católica Portuguesa
|Supervisor||Gustavo Fernandes (Supervisor) & Rogerio Moraes Castilho (Co-Supervisor)|
- Sclerostin antibody
- Bone remodeling
- Bone formation
- Mestrado em Medicina Dentária